Clinical Trial Update: Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML [Phase 2]

View source ↗

Summary

Phase 2 dosing study in refractory and relapsed acute myeloid leukemia evaluating the Ara-C/EL625/idarubicin combination; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• EL625
• Idarubicin (idarubicin)

Snippet

Sponsor: Eleos, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED